| Package Design: | Own Designer |
|---|---|
| Transport Package: | Cartons |
| Specification: | 10mg, 25mg, 200mg |
| Trademark: | Mifepristone Misoprostol Tablets |
| Origin: | China |
| Samples: |
|---|
Suppliers with verified business licenses
Audited Supplier Mifepristone Tablets 25MG - Anti-early Pregnancy Drug
| Product Name | Mifepristone Tablets Misoprostol Tablets |
| Specification | 10mg, 25mg, 200mg |
| Packing | 6 tablets per Alu-Alu tray |
| Indication | Anti-early Pregnancy Tablet for Gynaecology |
Main ingredient: Mifepristone.
Properties:This product is a slightly yellow tablet.
Indications:
This product is indicated for the sequential use of mifepristone tablets in combination with prostaglandin drugs for the termination of pregnancy within 49 days of menopause.
Dosage:
For healthy women with early pregnancy ≤ 49 days of menopause, take 25-50mg of Mifepristone tablets orally twice a day for 2-3 days after 2 hours of fasting or food, for a total of 150mg, fasting for 2 hours after each dose. Bed rest for 1-2 hours and outpatient observation for 6 hours. Watch for bleeding after administration, any pregnancy products excretion and side effects.
Adverse Reactions:
1. Rash may occur in individual women.
2. Abdominal pain may occur after the use of prostaglandins, vomiting and diarrhoea may occur in some subjects.
3. A few women may experience flushing and numbness.
4,Some women with early pregnancy have mild nausea, vomiting, dizziness, weakness and lower abdominal pain, anal cramping and uterine bleeding after taking the drug.
Contraindications
1. Hypersensitivity to this product.
2, Patients with cardiac, hepatic or renal disease and adrenal cortical insufficiency.
3. Those with contraindications to the use of prostaglandins: e.g. glaucoma, asthma and allergy to prostaglandins.
4. Pregnancy with an intrauterine device and suspected ectopic pregnancy, and women over 35 years of age who smoke.
Precautions:
1. In cases of confirmed normal intrauterine pregnancy, the number of days of menopause should not exceed 49 days and the maximum should not exceed 56 days.
2. Mifepristone tablets must be used in clinical units with conditions for emergency care, curettage procedures and infusion of fluids and blood. Please use under medical supervision.
3. The person taking the medicine must be informed in detail of the therapeutic effects and possible side effects before taking the medicine.
4. After taking the medicine, a small amount of vaginal bleeding usually occurs earlier, and some women have longer bleeding after abortion. A small number of women with early pregnancy can abort spontaneously after taking mifepristone tablets. About 80% of pregnant women expel the chorion or fetal sac within 6 hours after using prostaglandin-based drugs, and about 10% of pregnant women expel the pregnancy within a week after taking the drug.
5. A follow-up visit to the original treatment unit should be made 8-15 days after taking the medication to determine the effect of abortion. If necessary, ultrasound examination or blood beta human chorionic gonadotropi n (HCG) measurement should be carried out to confirm the diagnosis of incomplete abortion or continued pregnancy.
6. If the use of this product fails to terminate early pregnancy, abortion must be performed.
7. Use in pregnant and lactating women: Not recommended except for termination of early pregnancy.
8. Use in children: There is a lack of information on the safety and efficacy of this product for use in children.
9. Geriatric use: There is a lack of data on the safety and efficacy of this product in elderly patients.
10. Overdose: According to the literature, no serious adverse reactions have been reported in tolerability studies with a single oral dose of 1800 mg of mifepristone given to healthy non-pregnant women and male subjects. If a patient ingests substantially more than the dose, signs of adrenal failure should be closely monitored.
Drug Interactions:
Avoid taking aspirin and other NSAIDs within 1 week of taking this product.
Pharmacological Effects:
Mifepristone is an anti-progestational agent at the receptor level, which has the effect of terminating early pregnancy, anti-septogenesis, inducing menstruation and promoting cervical maturation, competing with progesterone for receptors to antagonize progesterone and binding to glucocorticoid receptors. Mifepristone can significantly increase the sensitivity of the pregnant uterus to prostaglandins. Small doses of mifepristone combined with prostaglandins in a sequential manner can achieve satisfactory termination of early pregnancy.
Pharmacokinetics:
Mifepristone 25mg is rapidly absorbed orally, with a mean time to peak of 0.9±0.5 hours and a mean peak blood dose of 1.1±0.41mg/L, showing significant individual differences. The elimination half-life is 26 hours. Non-pregnant women generally have a faster time to peak, higher blood levels and longer elimination half-life. There is a significant first pass effect and blood levels of metabolites can already exceed the parent compound 1-2 hours after oral administration.
Storage:
Store in a sealed container, protected from light.
Expiry date:60 months
TENAS MEDICINE is a group of professional pharmaceutical manufacturing personnel, accumulated rich experience in production, quality and management.
We offer a wide range of quality products including tablets, capsules, soft gel caps, syrups, injectables, infusions, ointments, protein powders, nutritional combinations and herbal combinations in very attractive and elegant packaging.
With the efforts of all members, the products are exported to Africa, South America, Central America, Middle East countries, as well as some southeast Asian countries.
Safety, purity, efficacy and accuracy of ingredients are often some of the salient features of our medicines. Each product is made using top-ranked ingredients and ingredients under the supervision of a medical expert. Our organization is fortunate to have highly skilled professionals who devote significant expertise and experience to leading organizations in providing the highest quality medicines.
More than 200 products have been registered outside China. Our factories are established according to GMP standards and have passed MOH tests in more than 20 countries.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}